Protective Role of Myricetin and Fisetin Against Nephrotoxicity Caused by Lead Acetate Exposure Through Up-Regulation of Nrf2/Ho-1 Signalling Pathway

dc.contributor.author Berkoz, Mehmet
dc.contributor.author Yigit, Ayhan
dc.contributor.author Krosniak, Miroslaw
dc.date.accessioned 2025-05-10T17:18:07Z
dc.date.available 2025-05-10T17:18:07Z
dc.date.issued 2024
dc.description Berkoz, Mehmet/0000-0003-4219-8054 en_US
dc.description.abstract The effect of various flavonoids against oxidative stress and inflammation caused by lead exposure has been investigated. However, the protective effects of myricetin (MYC) and fisetin (FST), which are known to have potent antioxidant properties, against nephrotoxicity caused by exposure to lead acetate (LA), the water-soluble form of lead, have not been investigated. Our study investigated the protective role of these flavonoids against LA intoxication-induced nephrotoxicity. In our study, 42 male rats were used. The rats were randomly selected and divided into 6 groups. These groups were: control, LA (100 g/kg), LA + MYC (100 mg/kg), LA + MYC (200 mg/kg), LA + FST (100 mg/kg) and LA + FST (200 mg/kg). All chemicals were administered daily by gavage for 28 days. According to the experimental protocol, the animals were sacrificed and their kidney tissues were isolated. Serum biochemical parameters, histological examinations, levels of several trace elements, oxidative stress and inflammatory parameters at both biochemical and molecular levels in kidney tissues were examined. After LA administration, tissue lead levels increased and zinc levels decreased. This situation was reversed by MYC and FST treatment. Oxidative stress and inflammatory response were increased in the kidney tissue of LA-treated rats and renal function was impaired. It was observed that both doses of MYC and high dose of FST could prevent nephrotoxicity. Oral administration of both doses of MYC and high dose FST ameliorated the changes in biochemical, oxidative and inflammatory parameters. Restoration of normal renal tissue architecture was also demonstrated by histological studies. MYC and FST were found to have promising biological activity against LA-induced nephrotoxicity, acting by attenuating inflammation and oxidative stress and improving antioxidant status. en_US
dc.description.sponsorship Office of Scientific Research Projects of Van Yuzuncu Yil University [TYL-2021-8970] en_US
dc.description.sponsorship This research was financially supported by the Office of Scientific Research Projects of Van Yuzuncu Yil University under Grant number [TYL-2021-8970]. en_US
dc.identifier.doi 10.1007/s12011-023-03977-6
dc.identifier.issn 0163-4984
dc.identifier.issn 1559-0720
dc.identifier.scopus 2-s2.0-85178933751
dc.identifier.uri https://doi.org/10.1007/s12011-023-03977-6
dc.identifier.uri https://hdl.handle.net/20.500.14720/9577
dc.language.iso en en_US
dc.publisher Springernature en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Lead Acetate en_US
dc.subject Nephrotoxicity en_US
dc.subject Myricetin en_US
dc.subject Fisetin en_US
dc.subject Nrf2/Ho-1 Signalling Pathway en_US
dc.title Protective Role of Myricetin and Fisetin Against Nephrotoxicity Caused by Lead Acetate Exposure Through Up-Regulation of Nrf2/Ho-1 Signalling Pathway en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Berkoz, Mehmet/0000-0003-4219-8054
gdc.author.scopusid 12801030200
gdc.author.scopusid 57223185228
gdc.author.scopusid 6602345446
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp [Berkoz, Mehmet; Yigit, Ayhan] Van Yuzuncu Yil Univ, Fac Pharm, Dept Biochem, Zeve Campus, TR-65080 Van, Turkiye; [Krosniak, Miroslaw] Jagiellonian Univ, Med Coll, Dept Food Chem & Nutr, Krakow, Poland en_US
gdc.description.endpage 4046 en_US
gdc.description.issue 9 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q1
gdc.description.startpage 4032 en_US
gdc.description.volume 202 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q2
gdc.identifier.pmid 38051478
gdc.identifier.wos WOS:001113136200001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed

Files